Sponsored by:

Nuclear Medicine: Page 168

Naviscan touts clinical study results
By AuntMinnie.com staff writers
PET developer Naviscan is highlighting clinical trial results that show positron emission mammography (PEM) imaging with a breast-cancer-specific tracer achieved 100% sensitivity.
July 24, 2013
Misdiagnosis of Alzheimer's can cost big money
By Wayne Forrest
Receiving a misdiagnosis of Alzheimer's disease can result in tens of thousands of dollars in unnecessary medical costs for patients who actually have vascular dementia or Parkinson's disease, according to a study presented on July 17 at the Alzheimer's Association International Conference in Boston.
July 22, 2013
NOPR leaves legacy of cancer coverage and cooperation
By Wayne Forrest
The seven-year initiative known as the National Oncologic PET Registry (NOPR) began to wind down its operation after the U.S. Centers for Medicare and Medicaid Services announced last month it would halt the data collection requirement for all oncologic indications for FDG-PET as a condition of reimbursement.
July 22, 2013
2013 07 18 10 38 13 983 Siegel Barry 200
UPPI names Witkowski as president
By AuntMinnie.com staff writers
Nuclear pharmacy network United Pharmacy Partners (UPPI) has named John Witkowski Jr. as its new president.
July 18, 2013
AuntMinnie.com Molecular Imaging Insider
By Wayne Forrest
July 17, 2013
RadNet signs on for Alzheimer's drug trial
By AuntMinnie.com staff writers
Imaging services firm RadNet will participate in a clinical trial for E2609, an investigational drug being developed by Japanese pharmaceutical firm Eisai for the treatment of Alzheimer's disease.
July 16, 2013
PiB-PET scans shed light on role of plaque in Alzheimer's
By AuntMinnie.com staff writers
The trajectory of amyloid plaque buildup may be a more powerful biomarker for cognitive decline than the total amount of plaque, according to a study published online July 15 in Neurobiology of Aging.
July 15, 2013
Navidea touts Australian Alzheimer's study
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals said that an Australian clinical study plans to switch the radiopharmaceutical it is using to Navidea's NAV4694 beta-amyloid imaging candidate.
July 15, 2013
Gamma Medica wraps up financing
By AuntMinnie.com staff writers
Gamma Medica said it has closed on a $16 million series A financing round from healthcare investment firm Psilos Group Managers.
July 15, 2013
Florbetapir shows promise in detecting cardiac amyloid
By Wayne Forrest
Preliminary study results indicate that F-18 florbetapir (Amyvid) can detect cardiac amyloidosis, a buildup of protein that can lead to various forms of heart disease. The results hint that Amyvid could be useful beyond its core indication of detecting beta-amyloid deposits in the brain.
July 15, 2013
Japanese government reimburses for PEM scans
By AuntMinnie.com staff writers
PET developer Naviscan announced that its Japanese distributor, SCETI, has received notification of reimbursement approval for Naviscan's positron emission mammography (PEM) scanner.
July 14, 2013
Radiopharma market may triple in 5 years
By AuntMinnie.com staff writers
New technological developments and research are poised to nearly triple the size of the radiopharmaceutical market by 2018, according to a new report by Transparency Market Research.
July 11, 2013
Previous Page
Page 168 of 439
Next Page